Antineoplastic treatment with crizotinib during pregnancy: a case report

Kristian H. JensenDepartment of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark; Correspondence[email protected]

Gitte PerssonDepartment of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark;

Lone StorgaardDepartment of Obstetrics, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark;

Birgitte B. NielsenDepartment of Obstetrics, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark;

Berit W. PedersenDepartment of Obstetrics, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark;

Lisa L. MarounDepartment of Pathology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark;

Alwin HuitemaDepartment of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; ;Department of Clinical Pharmacy, University Medical Center Utrecht Utrecht University, Utrecht, The Netherlands

Mette PøhlDepartment of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark;

show all

References

Dagogo-Jack I, Gainor JF, Porter RL, et al. Clinicopathologic features of NSCLC diagnosed during pregnancy or the peripartum period in the era of molecular genotyping. J Thorac Oncol. 2016;11:1522–1528.
PubMed Web of Science ®Google Scholar
Kwon J, Meagher A. Crizotinib: a breakthrough for targeted therapies in lung cancer. J Adv Pract Oncol. 2012;3:267–272.
PubMedGoogle Scholar
Eliesen GAM, van den Broek P, van den Heuvel JJ, et al. Highlight: placental disposition and effects of crizotinib: an ex vivo study in the isolated dual-side perfused human cotyledon. Toxicol Sci. 2017;157:500–509.
PubMed Web of Science ®Google Scholar
Tang SC, Nguyen LN, Sparidans RW, et al. Increased oral availability and brain accumulation of the ALK-inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014;134:1484–1494.
PubMed Web of Science ®Google Scholar
Su HI, Connell MW, Bazhenova LA. Ovarian stimulation in young adult cancer survivors on targeted cancer therapies. Fertil Steril. 2016;106:1475–1478.
PubMed Web of Science ®Google Scholar
Bartsch E, Medcalf K, Park A, et al. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. 2016;353:i1753.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Antineoplastic treatment with crizotinib during pregnancy: a case report

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Antineoplastic treatment with crizotinib during pregnancy: a case report

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date